Comparative Effectiveness of Dual Biologic Therapy and Biologic Small‐Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single‐Center Study
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70198 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Fan Yin und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xij…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Biological Therapy, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Patients with refractory inflammatory bowel disease (IBD) face difficulty in the treatment strategy. Combined advanced targeted therapies may obtain higher therapeutic efficacy. However, few studies compare the efficacy and safety of dual biologic therapy (DBT) with biologic small‐molecule therapy (BMT) for refractory IBD. We aimed to compare the effectiveness of DBT with BMT. We retrospectively analyzed the data of patients with refractory IBD treated with DBT ( n = 22) or BMT ( n = 21). The primary outcome was the clinical remission rate at week 12. Secondary outcomes included the clinical response rate, endoscopic response rate, endoscopic remission rate, colectomy rate, and rate of adverse events (AEs) at week 12. At week 12, the clinical remission rates in the DBT group and BMT group were 22.7% and 28.6%, respectively. No statistically significant difference was observed between the two groups ( p = 0.661). There were also no statistically significant differences between the DBT group and BMT group in the clinical response rate (68.2% vs. 71.4%, p = 0.817), endoscopic response rate (66.7% vs. 68.8%, p = 1.000), endoscopic remission rate (4.8% vs. 18.8%, p = 0.296) and colectomy rate (4.5% vs. 23.8%, p = 0.167). Two patients (9.5%) in the BMT group and no patients in the DBT group experienced AEs. However, the difference was not statistically significant ( p = 0.233). In conclusion, this study revealed that there may be similar effectiveness and safety of DBT and BMT for patients with refractory IBD. Further multi‐center, prospective randomized controlled trials are necessary to confirm this conclusion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Military Medical Univers…
- Department of Gastroenterology, Guang'an People's Hospital, Guang'an, China.
- Department of Medical Insurance, Xijing Hospital, Air Force Military Medical University, Xi'an, China.
ORCID-Profile: Min Chen
Zitieren
APA
Yin, F., Liu, X., He, D., Li, S., Feng, X., Shi, Y., & Chen, M. (2025). Comparative Effectiveness of Dual Biologic Therapy and Biologic Small‐Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single‐Center Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70198
Vancouver
Yin F, Liu X, He D, Li S, Feng X, Shi Y, et al. Comparative Effectiveness of Dual Biologic Therapy and Biologic Small‐Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single‐Center Study. Clinical and Translational Science. 2025. doi:10.1111/cts.70198
BibTeX
@article{Yin2025,
author = {Yin, Fan and Liu, Xiaolei and He, Dongdong and Li, Songbo and Feng, Xin and Shi, Yongquan and Chen, Min},
title = {Comparative Effectiveness of Dual Biologic Therapy and Biologic Small‐Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single‐Center Study},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70198}
}
EUVIMED